Zupervise appoints Oliver Smith as Strategic Adviser

We are thrilled to announce the appointment of Oliver Smith as Strategic Adviser.
This comes at a pivotal time for Zupervise. We are now seeing tremendous market interest from customers in an exciting new vertical. Oliver will play a key role in shaping our go-to-market strategy in digital health. His deep understanding of the industry and its regulatory requirements will be instrumental in guiding our customers to achieve compliance and foster trust with regulators, clinicians & patients.

The use of AI in digital health raises a number of ethical and regulatory questions, including:
  • Data privacy: With the increasing use of patient data in AI algorithms, it is important to ensure that this data is collected, stored, and used in a manner that is consistent with patient privacy, consent and confidentiality.
  • Bias: It is increasingly understood that a biased training set leads to biased algorithms, but this is not the whole story; design and implementation decisions can also significantly affect algorithmic bias. Validation is therefore required at each stage of model development and deployment.
  • Explainability and transparency: The complex nature of AI models can make it difficult to understand how they make decisions. Not only is this a concern for regulators but it can undermine clinical trust, leading to poor real-world use which then negatively impacts on the business case. It is important to ensure that AI algorithms are designed to be transparent and explainable, so that the decisions they make can be understood, evaluated, and ultimately trusted by regulatory agencies, clinicians, patients, and other stakeholders.

The U.S. Food and Drug Administration (FDA), Health Canada, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) have jointly identified 10 guiding principles that can inform the development of Good Machine Learning Practice (GMLP). In addition, the MHRA has published its roadmap for regulating software as a medical device (SaMD) and artificial intelligence as a medical device (AIaMD).

Available in beta now, our flagship industry solution for digital health, Zupervise’s
AI Trust Monitor is designed to ensure Safety, Transparency, and Trust in AI.

We use cookies to enhance site navigation, analyse usage & assist in marketing.